filgotinib

Gilead Sciences, Inc. (NASDAQ: GILD) faces a regulatory setback as filgotinib,  an investigational drug it is co-developing with GALAPAGOS NV/S ADR (NASDAQ: GLPG), received a thumbs-down from the FDA. The Gilead Analyst: BofA Securities analyst Geoff Meacham reiterated a Neutral...

GALAPAGOS NV/S ADR (NASDAQ: GLPG) and Gilead Sciences, Inc. (NASDAQ: GILD) were advancing strongly Wednesday following the release of clinical trial data for their pipeline candidate filgotinib. Galapagos shares were rallying 17.95 percent to $121.18 at the time of publication, while Gilead was up...

Shares of Gilead Sciences, Inc. (NASDAQ: GILD) were trading lower by more than 2 percent Wednesday morning after the company's first quarter earnings and revenue fell short of what analysts were expecting. Although Gilead's numbers point to a top-and-bottom line beat, Barclays' Geoff...

Janney has initiated coverage of Galapagos NV (ADR) (NASDAQ: GLPG) with a Buy rating and fair value estimate of $64, citing potential success of Filgotinib. Galapagos has deals with Gilead Sciences, Inc. (NASDAQ: GILD) and AbbVie Inc (NYSE: ABBV) for the development of Filgotinib in inflammatory...

The IPO boom has raised billions of dollars for promising biotech developers who make compelling pitches to investors. A most recent example was Aduro BioTech Inc (NASDAQ: ADRO)'s sizzling IPO that raised a higher-than-expected $119 million in mid-April this year. The clinical-stage biotech...